PHARMA BIEN-ÊTRE
PHARMA BIEN-ÊTRE is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2024 annual accounts show equity of €770k and a net result of €241k. Equity is growing by ~41.3% per year across the filed fiscal years. Its solvency ranks better than 25% of 678 sector peers (fiscal year 2024). The company has been active since 2021 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €770k |
| Net result | €241k |
| Better than sector | 25% |
| Active | 4 yrs |
Mixed profile: strong on profitability, weaker on health.
This is a financial institution (bank, insurer or financial holding). Our bankruptcy model is trained on ordinary trading and manufacturing companies; a bank balance sheet falls outside that scope. We therefore show no bankruptcy probability rather than a misleading figure.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 18.3% | 44.9% | |
| Net result | €241k | €48k | |
| Equity | €770k | €1.36M | |
| Gross operating margin | €218k | €42k | |
| Total assets | €4.21M | €5.58M |
| Fiscal year | 2024 |
|---|---|
| Revenue | n/a |
| EBITDA | n/a |
| Net profit | €241k |
| Cash flow | n/a |
| Staff costs | - |
| Income taxes | €34k |
| Dividends | - |
| Total assets | €4.21M |
| Equity | €770k |
| Debt | €3.44M |
| of which ≤ 1y | €358k |
| of which > 1y | €3.09M |
| Working capital | n/a |
| Employees (FTE) | - |
| 2024 | |
|---|---|
| Current ratio | n/a |
| Quick ratio | n/a |
| Working capital ratio | n/a |
| Solvency | 18.3% |
| Debt / equity | n/a |
| Long-term debt ratio | n/a |
| Interest coverage | n/a |
| Gross margin | n/a |
| Net margin | n/a |
| ROA | 5.7% |
| ROE | 31.3% |
| EBITDA margin | n/a |
| Days sales outstanding | n/a |
| Days payable outstanding | n/a |
| Inventory turnover | n/a |
| Days inventory (DSI) | n/a |
| Line item | Code | 2024 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €4.21M |
| Fixed assets | 21/28 | €3.95M |
| Tangible fixed assets | 22/27 | €425k |
| Financial fixed assets | 28 | €3.53M |
| Current assets | 29/58 | €260k |
| Amounts receivable within one year | 40/41 | €183k |
| Investments | 50/53 | €31k |
| Cash & bank | 54/58 | €45k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €4.21M |
| Equity | 10/15 | €770k |
| Contributions / capital | 10/11 | €200k |
| Reserves | 13 | €245k |
| Accumulated profits (losses) | 14 | €325k |
| Amounts payable | 17/49 | €3.44M |
| Amounts payable after one year | 17 | €3.09M |
| Amounts payable within one year | 42/48 | €358k |
| Trade debts payable within one year | 44 | €6k |
| Income statement | ||
| Gross operating margin | 9900 | €218k |
| Operating result | 9901 | €201k |
| Financial income | 75 | €129k |
| Financial charges | 65 | €55k |
| Result before taxes | 9903 | €275k |
| Income taxes | 67/77 | €34k |
| Net result for the period | 9904 | €241k |
| Result to be appropriated | 9905 | €241k |
| NACE primary | Financial services(64210) |
| Legal form | Public limited company(014) |
| Incorporation | 28-10-2021 |
| Status | Active |
| Postal code | 5100 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 92322E0536/00V000 | Wallonia | 1,318 m² | - | - |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
13-08-2025 Registered office moved to Jambes
- Rue de Sedent 205, boîte 21 à 5100 Jambes
Technical details
{
"events": [
{
"kind": "zetel_transfer",
"seat_type": "siege_social",
"new_address": {
"raw": "Rue de Sedent 205, bo\u00EEte 21 \u00E0 5100 Jambes",
"city": "Jambes",
"region": "waals_gewest",
"street": "Rue de Sedent",
"country": "BE",
"postcode": "5100",
"box_number": "21",
"street_number": "205",
"locality_suffix": null
},
"old_address": null,
"effective_date": "2025-07-01",
"evidence_quote": "L\u0027administrateur unique confirme avoir proc\u00E9d\u00E9 au transfert du si\u00E8ge de la Soci\u00E9t\u00E9 (ainsi que du si\u00E8ge d\u0027exploitation), \u00E0 l\u0027adresse suivante, et ce \u00E0 dater du 1er juillet 2025:",
"region_changed": false,
"is_statute_change": true,
"nationality_change": true,
"old_address_source": "inferred",
"statute_clause_text": null,
"statute_article_number": null,
"effective_date_qualifier": "absolute",
"statutaire_vs_werkelijke": "statutaire",
"linguistic_region_changed": false,
"court_jurisdiction_changed": false,
"effective_date_is_approximate": false
}
],
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": null,
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": "2025-08-13",
"filing_date": "2025-07-16",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "enig_aandeelhouder_schriftelijk",
"date": "2025-07-16",
"unanimous": true
},
"subject_company": {
"kbo": "0776.600.905",
"name_full": "Pharma Bien-\u00EAtre",
"legal_form": "Soci\u00E9t\u00E9 anonyme"
},
"publication_proxy": {
"kind": "org",
"org_kbo": null,
"org_name": "DELOITTE ACCOUNTANCY SRL",
"person_name": null,
"org_rep_person_name": null,
"person_role_at_subject": null
},
"co_filed_documents": [
"Bijlagen bij het Belgisch Staatsblad",
"Annexes du Moniteur belge"
]
}09-02-2023 Registered office moved to Namur
- Chemin des mélèzes 15 à 5000 Namur
Technical details
{
"events": [
{
"kind": "zetel_transfer",
"seat_type": "combined",
"new_address": {
"raw": "Chemin des m\u00E9l\u00E8zes 15 \u00E0 5000 Namur",
"city": "Namur",
"region": "waals_gewest",
"street": "Chemin des m\u00E9l\u00E8zes",
"country": "BE",
"postcode": "5000",
"box_number": "5",
"street_number": "15",
"locality_suffix": null
},
"old_address": null,
"effective_date": "2023-01-12",
"evidence_quote": "L\u0027administrateur unique d\u00E9cide de proc\u00E9der au transfert du si\u00E8ge (ainsi que du si\u00E8ge d\u0027exploitation) l\u0027adresse suivante, et ce \u00E0 dater du 12 janvier 2023:",
"region_changed": false,
"is_statute_change": true,
"nationality_change": true,
"old_address_source": "inferred",
"statute_clause_text": null,
"statute_article_number": null,
"effective_date_qualifier": "absolute",
"statutaire_vs_werkelijke": "statutaire",
"linguistic_region_changed": false,
"court_jurisdiction_changed": false,
"effective_date_is_approximate": false
}
],
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": null,
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": null,
"filing_date": "2023-01-31",
"act_kind_objet": "Objet de l\u0027acte:"
},
"decision": {
"body": "enig_aandeelhouder_schriftelijk",
"date": "2023-01-26",
"unanimous": true
},
"subject_company": {
"kbo": "0776.600.905",
"name_full": "PHARMA BIEN-\u00CATRE",
"legal_form": "SA"
},
"publication_proxy": {
"kind": "org",
"org_kbo": null,
"org_name": "Deloitte Accountancy SRL",
"person_name": null,
"org_rep_person_name": "Julie Decelle",
"person_role_at_subject": null
},
"co_filed_documents": [
"Copie \u00E0 publier aux annexes au Moniteur belge apr\u00E8s d\u00E9p\u00F4t de l\u0027acte au greffe"
]
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameFR | PHARMA BIEN-ÊTRE |